Cannabis use: A perspective in relation to the proposed UK drug-driving legislation

Drug Testing and Analysis

Volumn 6, Issue 1-2, 2014, Pages 143-154

  Wolff, Kim ^a   Johnston, Atholl ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Blood; Cannabis; Drug driving; per se threshold; Road traffic collision; THC

Indexed keywords

AUTOMOBILE DRIVERS; BLOOD; MOTOR TRANSPORTATION; ROADS AND STREETS;

BLOOD; CANNABIS; CANNABIS SATIVA L; DRIVING PERFORMANCE; DRIVING UNDER THE INFLUENCE; DRUG-DRIVING; ILLEGAL DRUGS; PER SE THRESHOLD; ROAD TRAFFIC COLLISIONS; Δ9-TETRAHYDROCANNABINOL;

DIGITAL STORAGE;

ALCOHOL; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; CONTROLLED SUBSTANCE; DRONABINOL; ILLICIT DRUG; NABILONE; NABIXIMOLS; PLACEBO; TETRAHYDROCANNABINOL;

ALCOHOL BLOOD LEVEL; ALERTNESS; ATTENTION; BLOOD SAMPLING; CANNABIS SMOKING; CANNABIS USE; CAR DRIVING; COGNITIVE DEFECT; DRIVING ABILITY; DRUG BIOAVAILABILITY; DRUG CONCENTRATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; LAW; LIMIT OF DETECTION; LIMIT OF QUANTITATION; META ANALYSIS (TOPIC); MOTOR COORDINATION; NONHUMAN; PHARMACOKINETICS; PREVALENCE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; REVIEW; TIME PERCEPTION; TRAFFIC ACCIDENT; UNITED KINGDOM;

BLOOD; CANNABIS; DRUG-DRIVING; PER SE THRESHOLD; ROAD-TRAFFIC-COLLISION; THC;

ACCIDENTS, TRAFFIC; AUTOMOBILE DRIVING; CANNABINOID RECEPTOR AGONISTS; DRONABINOL; HUMANS; MARIJUANA SMOKING;

EID: 84892454299     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1588     Document Type: Review

References (142)

1. United Nations Office on Drug and Crime. UN World Drug Report. UN, 2011, Vienna, Italy, pp. 11-18.
2. Department for Transport. Reported Road Casualties in Great Britain, 2011 Annual Report, Transport Statistics publications, DfT, Gwent, Wales.
3. Department for Transport, Sir Peter North. Report of the Review of Drink and Drug Driving Law, 2010, Queen's Printer and Controller of Her Majesty's Stationery Office, dft publications. ISBN 9781 84864 0993.
4. M.F. Andreasen, J.B. Hasselstrom, I. Rosendal Prevalence of Licit and Illicit drugs in whole blood among Danish Drivers in Western Denmark. SOFT-TIAFT, San Francisco, 2011.
5. T. Assum, M.P. Mathijssen, S. Houwing, S.C. Buttress, R.J. Sexton, R.J. Tunbridge, R. Mathijssen, S. Houwing. The prevalence and relative risk of drink and drug driving in the Netherlands: a case control study in the Tilburg police district. Research of the European Research program IMMORTAL, 5th Framework Program. R-2005-9, 2nd Edition, Report No: D-R4, 2005, SWOV, Institute for Road Safety Research, Leidschendam, The Netherlands.
6. Drug Misuse Declared: Findings from the 2011/12 Crime Survey for England and Wales, 2nd Edn. Available at: http://www.homeoffice.gov.uk/publications/science-research-statistics/research-statistics/crime-research/drugs-misuse-dec-1112/drugs-misuse-dec-1112-pdf. [July 2013].
7. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug use impaired driving and traffic accidents. EMCDDA Insights Series No 8. Office for Official Publications of the European Communities, Luxembourg, 2008.
8. A.W. Jones, A. Holmgren, F.C. Kugelberg. Driving under the influence of cannabis: a 10-year study of age and gender differences in the concentrations of tetra hydrocannabinol in blood. Addiction 2008, 103, 452.
9. Driving under the Influence of Drugs, Alcohol and Medicines (DRUID). DRUID deliverable D3.2.2, Summary of main DRUID results: Driving under the influence of drugs, alcohol, and medicines, TRB 91ST Annual meeting, USA Dutch Forensic Institute Report, 2012.
10. V. Vindenes, D. Jordbru, A.B. Knapskog, E. Kvan, G. Mathisrud, L. Slørdal, J. Mørland. Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway. Forensic Sci. Int. 2012, 219, 1.
11. RRCGB. 2011 Annual Report. Self-reported drink and drug driving: Findings from the Crime Survey for England and Wales. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/9278/rrcgb2011-05.pdf [July 2013].
12. J. Neale, N. McKeganey, G. Hay, J. Oliver. Recreational drug use and driving: A qualitative study. The Scottish Executive Central Research Unit, The Stationery Office, Edinburgh, 2000
13. P. Terry, K. Wright. Self-reported driving behaviour and attitudes towards driving under the influence of cannabis among three different user groups in England. Addict. Behav. 2005, 30, 619.
14. S. Darke, E. Kelly, J. Ross. Drug driving among injecting drug users in Sydney, Australia: Prevalence, risk factors and risk perceptions. Addiction 2004, 99, 175.
15. C. Jones, N. Donnelly, W. Swift, D. Weatherburn. Driving under the influence of cannabis: The problem and potential countermeasures. Crime Justice Bull. 2004, 87, 1.
16. Driving under the influence of drugs. The report of the Department for Transport Expert Panel. Available at: https://www.gov.uk/government/publications/ driving-under-the-influence-of-drugs--2. [July 2013].
17. P. Sharma, P. Murthy, M.M. Bharath. Chemistry, metabolism, and toxicology of cannabis: Clinical implications. Iran J. Psychiat. 2012, 7, 149.
18. I. Kurzthaler, M. Hummer, C. Miller, B. Sperner-Unterweger, V. Günther, H. Wechdorn, H.J. Battista, W.W. Fleischhacker. Effect of cannabis use on cognitive functions and driving ability. J. Clin. Psychiatry 1999, 60, 395.
19. G. Berghaus, B. Guo. Medicines and driver fitness--findings from a meta-analysis of experimental studies as basic information to patients, physicians and experts. in Alcohol, Drugs, and Traffic Safety--T95: Proceedings of the 13th International Conference on Alcohol, Drugs and Traffics Safety (Eds: C. Kloeden, A. McLean) Adelaide, Australia, 1995, NHMRC Road Accident Research Unit. ISBN 090820413 pp. 295-300.
20. M.N. Bates, T.A. Blakely. Role of cannabis in motor vehicle crashes. Epidemiol. Rev. 1999, 21, 222.
21. G. O'Kane, D.C. Tutt, L.A. Bauer. Cannabis and driving: A new perspective. Emerg. Med. 2002, 14, 296.
22. L.R. Sutton. The effects of alcohol, marihuana and their combination on driving ability. J. Stud. Alcohol 1983, 44, 438.
23. R.A. Sewell, J. Poling, M. Sofuoglu. The effect of cannabis compared with alcohol on driving. Am. J. Addict. 2009, 18, 185.
24. J.G. Ramaekers, G. Berghaus, M. van Laar, O.H. Drummer. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend. 2004, 73, 109.
25. M. Asbridge, C. Poulin, A. Donato. Motor vehicle collision risk and driving under the influence of cannabis: Evidence from adolescents in Atlantic Canada. Accident Anal. Prev. 2005, 37, 1025.
26. S. Blows, R. Ivers, M. Woodward, J. Connor, S. Ameratunga, R. Norton. Vehicle year and the risk of car crash injury. Inj. Prev. 2003, 9, 353.
27. K.L. Movig, M.P. Mathijssen, P.H. Nagel, T. van Egmond, J.J. de Gier, H.G. Leufkens, A.C. Egberts, Psychoactive substance use and the risk of motor vehicle accidents. Accident Anal. Prev. 2004, 36, 631.
28. M. Bédard, S. Dubois, B. Weaver. The Impact of Cannabis on Driving. Revue Canadienne De Sante Publique 2007, 98, 6.
29. B. Laumon, B. Gadegbeku, J.L. Martin, M.B. Biecheler. Cannabis intoxication and fatal road crashes in France: Population based case-control study. Brit. Med. J. 2005, 331, 1371.
30. P. Mura, P. Kintz, B. Ludes, J.M. Gaulier, P. Marquet, S. Martin-Dupont, F. Vincent, A. Kaddour, J.P. Goulle, J. Nouveau, M. Moulsma, S. Tilhet-Coartet, O. Pourrat. Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: Results of a French collaborative study. Forensic Sci. Int. 2003, 133, 79.
31. O.H. Drummer, J. Gerostamoulos, H. Batziris, M. Chu, J. Caplehorn, M.D. Robertson, P. Swann. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accidnte Anal. Prev. 2004, 36, 239.
32. S. Blows, R.Q. Ivers, J. Connor, S. Ameratunga, M. Woodward, R. Norton. Marijuana use and car crash injury. Addiction 2005, 100, 605.
33. Driving under the Influence of Drugs, Alcohol and Medicines (DRUID). Main results to be communicated to different target groups. Available at: http://www.druid-project.eu/cln_031/nn_107548/Druid/EN/ deliverables-list/downloads/Deliverable __7__3__2, templateId=raw, property=publicationFile. pdf/ Deliverable_7_3_2.pdf. [July 2013].
34. G. Gmel, H.A. Kuendig, J.A. Rehm, N. Schreyer, J.B. Daeppen. Alcohol and cannabis use as risk factors for injury - a case-crossover analysis in a Swiss hospital emergency department. BMC Public Health 2009, 9, 40.
35. F.M. Fergusson, L.J. Horwood. Cannabis use and traffic accidents in a birth cohort of young adults. Accident Anal. Prev. 2001, 33, 703.
36. M.R.J. Baldock. Review of the literature on cannabis and crash risk (CASR010), Centre for Automotive Safety Research, Department for Transport, Energy and Infrastructure (SA), Adelaide, 2007.
37. M. Augsburger, N. Donzé, A. Ménétrey, C. Brossard, F. Sporkert, C. Giroud, P. Mangin. Concentration of drugs in blood of suspected impaired drivers. Forensic Sci. Int. 2005, 153, 11.
38. C. Giroud, A. Menetrey, M. Augsburger. Delta(9)-THC, 11-OHDelta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci. Int. 2001, 123, 159.
39. G. Jager. Cannabis. in Drug Abuse and Addiction in Medical Illness, (Eds: J.C. Vester, K. Brady, M. Galanter, P. Conrod), Springer, New York, 2012, pp. 151-162.
40. F.Grotenhermen. Harm reduction associated with inhalation and oral administration of cannabis and THC. J. Cannabis Ther. 2001, 1, 133.
41. S.R. Watchel, M.A. ELSohly, S.A. Ross, J. Ambre, H. de Wit. Comparison of the subjective effects of delta-(9) tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl) 2012, 161, 331.
42. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Literature Review on the Relation between Drug Use, Impaired Driving and Traffic Accidents. CT.97.EP.14 EMCDDA, Lisbon, 1999.
43. J.G. Bramness, H.Z. Khiabani, J. Mørland. Impairment due to cannabis and ethanol: clinical signs and additive effects. Addiction 2010, 105, 1080.
44. V.O. Von Leirer, J.A. Yesavage, D.G. Morrow. Marijuana carry-over effects on aircraft pilot performance. Aviat. Space Envir. Md. 1991, 62, 221.
45. H.Z. Khiabani, J.G. Bramness, A. Bjørneboe, J. Mørland. Relationship between THC concentration in blood and impairment in apprehended drivers. Traffic Inj. Prev. 2006, 7, 111.
46. R. Kronstrand, A.W. Jones. Drugs of abuse - analysis. in Encyclopedia of Forensic Sciences, (Eds: J.A. Siegel, P.J. Saukko, G.C. Knuffer), Academic Press, San Diego, CA, 2000, pp. 598-610.
47. T. Blencowe, A. Pehrsson, S. Mykkänen, T. Gunnar, P. Lillsunde. Cannabis findings in drivers suspected of driving under the influence of drugs in Finland from 2006 to 2008. Forensic Sci. Int. 2012, 217, 107.
48. J. Pulido, G. Barrio, P. Lardelli, M.J. Bravo, T.M. Brugal, A. Espelt, L. de la Fuente. Cannabis use and traffic injuries. Epidemiology 2011, 22, 609.
49. J. Pulido, G. Barrio, P. Lardelli, M.J. Bravo, E. Regidor, L. de la Fuente. Association between cannabis and cocaine use, traffic injuries and use of protective devices. Eur. J. Public Health 2011, 21, 753.
50. F. Grotenhermen, G. Leson, G. Berghaus, O.H. Drummer, H.P. Krüger, M. Longo, H. Moskowitz, B. Perrine, J.G. Ramaekers, A. Smiley, R. Tunbridge. Developing limits for driving under cannabis. Addiction 2007, 102, 1910.
51. G. Berghaus, E. Schulz, A. Szegedi. Cannabis und fahrtüchtigkeit. Ergebnisse der experimentellen forschung [Cannabis and driving skills: Results of experimental research]. in Cannabis im Straßenverkehr [Cannabis and Driving], (Eds: G. Berghaus, H.P. Krüger). Gustav Fisher Verlag, Stuttgart, 1998, pp. 73-97.
52. G. Berghaus, G. Sticht, W. Grellner, D. Lenz, T. Naumann, S. Wiesenmüller. Driving under the Influence of Drugs, Alcohol and Medicines (DRUID). 6th Framework programme, Deliverable 1.1.2b, Meta-analysis of empirical studies concerning the effects of medicines and illegal drugs including pharmacokinetics on safe driving. 2010, Transport RTD Program, University Wursburg, UWURZ, Germany.
53. Driving under the Influence of Drugs, Alcohol and Medicines (DRUID). Summary of main DRUID results, TRB 91ST Annual meeting, USA Dutch Forensic Science. Available at: http://www.drugscope.org.uk/Resources/Drugscope/Documents/PDF/Good%20Practice/cannabis_submission.pdf. [May 2013].
54. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual report on the state of the drugs problem in Europe. EMCDDA, Lisbon, November. Available at: www.emcdda.europa.eu/publications/annual-report/2010. [May 2013].
55. F.T. Pijlman, S.M. Rigter, J. Hoek, H.M. Goldschmidt, R.J. Niesink. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict. Biol. 2005, 10, 171.
56. Marijuana Growers Headquarters. How best to use medical marijuana. Available at: http://www.marijuanagrowershq.com/how-best-to-use-medical-marijuana-smoking-vs-edibles-and-tinctures/ [July 2013].
57. V. Vindenes, D.H. Strand, L. Kristoffersen, F. Boix, J. Mørland. Has the intake of THC by cannabis users changed over the last decade? Evidence of increased exposure by analysis of blood THC concentrations in impaired drivers. Forensic Sci. Int. 2013, 226, 197.
58. M. Perez-Reyes, S. Di Guiseppi, K.H. Davis, V.H. Schindler, C.E. Cook. Comparison of effects of marihuana cigarettes to three different potencies. Clin. Pharmacol. Ther. 1982, 31, 617.
59. S. MacDonald, R. Mann, M. Chipman, B. Pakula, P. Erickson, A. Hathaway, P. MacIntyre. Driving behaviour under the influence of cannabis or cocaine. Traffic Inj. Prev. 2008, 9, 190.
60. A.C. Moffat, M.D. Osselton, B. Widdop. in Clarke's Analysis of Drugs and Poisons, 3rd edn, Pharmaceutical Press, Bath, UK, 2004.
61. mg of THC in edibles. Bluelight >Focus Forums > Cannabis > Discussions >. http://www.bluelight.ru/vb/ archive/index.php/t-549317.html. v. Bulletin Version 4.1.12. [June 2013].
62. How best to use medicinal marijuana: Smoking vs Edibles and Tinctures. http://www.marijuanagrowershq.com/how-best-to-use-medical-marijuana-smoking-vs-edibles-and-tinctures/ [July 2013].
63. F. Grotenhermen, G. Leson. Reassessing the Drug Potential of Industrial Hemp. 2002, pp. 0-48. nova-Institut, Hürth, Germany.
64. S.E. Rooke, M.M. Norberg, J. Copeland, W. Swift W. Health outcomes associated with long-term regular cannabis and tobacco smoking. Addict. Behav. 2013, 38, 2207.
65. D. Reilly, R. Didcott, W. Swift, W. Hall. Long-term cannabis use: characteristics of users in Australian rural areas. Addiction 1998, 93, 837.
66. M. Kochanowski, M. Kała. Tetrahydrocannabinols in clinical and forensic toxicology(English Abstract). Przegl. Lek. 2005, 62, 576.
67. F. Musshoff, B. Madea. Review of biologic matrices (urine, blood, hair), as indicators of recent or On-going cannabis use. Ther. Drug Monit. 2006, 28, 155.
68. S. Agurell, M. Halldin. Pharmacokinetics and metabolism of 9 -tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharm. Rev. 1986, 38, 21.
69. A. Ohlsson, J.E. Lindgren, A. Wahlen, S. Agurell, L.E. Hollister, H.K. Gillespie. Single dose kinetics of deuterium labelled delta-1-tetrahydrocannabinol in heavy and light cannabis users. Biomed. Mass Spect. 1982, 9, 6.
70. A. Ohlsson, J.E. Lindgren, A. Wahlen, S. Agurell, L.E. Hollister, H.K. Gillespie. Plasma delta-9-tetrahydro- cannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther. 1980, 28, 409.
71. J.L. Azorlosa, M.K. Greenwald, M.L. Stitzer. Marijuana smoking: Effects of varying puff volume and breathhold duration. J. Pharmacol. Exp. Ther. 1995, 272, 560.
72. S.J. Gross, T.E. Worthy, L. Nerder, E.G. Zimmermann, J.R. Soares, P. Lomax. Detection of recent cannabis use by saliva delta 9-THC radioimmunoassay. J. Anal. Toxicol. 1985, 9, 1.
73. F. Grotenhermen. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 2003, 42, 327.
74. L.E. Hollister, H.K. Gillespie, A. Ohlsson, J.E. Lindgren, A. Wahlen, S. Agurell. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? J. Clin. Pharmacol. 1981, 21, 171S.
75. J.E. Manno, B.R. Manno, P.M. Kemp, D.D. Alford, I.K. Abukhalaf, M.E. McWilliams, F.N. Hagaman, M.J. Fitzgerald. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta-9-tetrahydrocannabinol, 11-hydroxy-delta-9-tetrahydro cannabinol, and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid. J. Anal. Toxicol. 2001, 25, 538.
76. M.A. Huestis, J.E. Henningfield, E.J. Cone. Blood cannabinoids: I. Absorption of THC and formation of 11-OH-THC and THC-COOH during and after marijuana smoking. J. Anal. Toxicol. 1992, 16, 276.
77. S. Harder, S. Rietbrock. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int. J. Clin. Pharm. Th. 1997, 35, 155.
78. S. Agurell, M. Halldin, J.E. Lindgren. Cannabis and cannabinoids in the treatment of cancer. Addiction 1996, 91, 1585.
79. B. Law, P.A. Mason, A.C. Moffat, R.I. Gleadle, L.J. King. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J. Pharm. Pharmacol. 1984, 36, 289.
80. S. Frytak, C.G. Moertel, J. Rubin. Metabolic studies of delta-9-tetrahydro cannabinol in cancer patients. Cancer Treat. Rep. 1984, 68, 1427.
81. 9-Tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction 2009, 104, 2041.
82. M.A. Huestis. Human cannabinoid Pharmacokinetics. Chem. Biodivers. 2007, 4, 1770.
83. E.L. Karschner, E.W. Schwilke, R.H. Lowe, W.D. Darwin, R.I. Herning, J.L. Cadet, M.A. Huestis. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J. Anal. Toxicol. 2009, 33, 469.
84. A.C. Moffat, M.D. Osselton, B. Widdop, Clarke's Analysis of Drugs and Poisons, 4th edn, London, 2011.
85. J.P. Goullé, E. Saussereau, C. Lacroix. Delta-9-tetra hydrocannabinol pharmacokinetics (English abstract). Ann. Pharm. Fr. 2008, 66, 232, DOI: 10.1016/j.pharma.2008.07.006. Epub 2008 Aug 29. Review.
86. M.E. Wall, B.M. Sadler. Metabolism, disposition, and kinetics of delta-9-tetrahydro cannabinol in men and women. Clin. Pharmacol. Ther. 1983, 34, 352.
87. E. Johansson, S. Agurell, L.E. Hollister, M.M. Halldin. Prolonged apparent half-life of delta 1-tetrahydro- cannabinol in plasma of chronic marijuana users. J. Pharm. Pharmacol. 1988, 40, 374.
88. 1-THC) in heavy users of marijuana. Eur. J. Clin. Pharm. 1989, 37, 273.
89. M.A. Peat. in Advances in Analytical Toxicology II (Ed: R.C. Baselt), Year Book Medical Publishers, Chicago, 1989, pp. 186.
90. H. Kalant. Adverse effects of cannabis on health: an update of the literature since 1996. Prog. Neuro-psychoph. 2004, 28, 849.
91. P. Kelly, R.T. Jones. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J. Anal. Toxicol. 1992, 16, 228.
92. A. Reiter, J. Hake, C. Meissner, J. Rohwer, H.J. Friedrich, M. Oehmichen. Time of drug elimination in chronic drug abusers. Case study of 52 patients in a " low-step" detoxification ward. Forensic Sci. Int. 2001, 119, 248.
93. G. Milman, D.M. Schwope, D.A. Gorelick, M.A. Huestis. Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. Clin. Chim. Acta 2012, 413, 765.
94. S.W. Toennes, J. Röhrich, C. Wunder. Interpretation of blood analysis data found after passive exposure to cannabis. Arch. Fur. Kriminologie. 2010, 225, 90.
95. J. Röhrich, I. Schimmel, S. Zörntlein, J. Becker, S. Drobnik, T. Kaufmann, V. Kuntz, R. Urban. Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydro cannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop. J. Anal. Toxicol. 2010, 34, 196.
96. K. Green, K. de Vries. Issues for pharmacists when patients use cannabis therapeutically at home. Pharm. J. 2012, 289, 531.
97. 9tetrahydro cannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy users but is not detected in standard field sobriety tests. Addiction 2012, 107, 1837.
98. Driving under the Influence of Drugs, Alcohol and Medicines (DRUID). Prevalence of alcohol and other psychoactive substances in injured and killed drivers, Deliverable D1.1.2b. Available at: http://www.west-info.eu/files/Druid-report-08-2011.pdf [May 2013].
99. E.L. Karschner, W.D. Darwin, R.S. Goodwin, S. Wright, M.A. Huestis. Plasma cannabinoid pharmacokinetics following controlled oral Δ9-Tetrahydrocannabinol and oromucosal cannabis extract administration. Clin. Chem. 2011, 57, 66.
100. I.J. McGilveray. Pharmacokinetics of cannabinoids. Pain Res. Manag. 2005, 10, 15A.
101. T. Kurzthaler, C. Bodner, G. Kemmler, T. Entner, J. Wissel, T. Berger, W.W. Fleischhacker. The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum. Psychopharmacol. 2005, 20, 291.
102. C.G. Stott, L. White, S. Wright, D. Wilbraham, G.W. Guy. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur. J. Clin. Pharmacol. 2013, 69, 1135.
103. F. Musshoff, B. Madea, G. Kernbach-Wighton, W. Bicker, S. Kneisel, M. Hutter, V. Auwärter. Driving under the influence of synthetic cannabinoids (" Spice"): A case series. Int. J. Legal Med. 2013, May 1, Epub ahead of print.
104. N. Langer, R. Lindigkeit, H.M. Schiebel, L. Ernst, T. Beuerle. Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: A snapshot of the German situation in the autumn of 2012. Drug Test. Anal. 2013, DOI: 10.1002/dta.1499
105. Association of Chief Police Officers (ACPO). Written evidence presented to the Advisory Council on the Misuse of Drugs. Available at: https://www.gov.uk/.../advisory-council-on-the-misuse-of-drugs [May 2013].
106. Talk-to-Frank. Advisory Council on the Misuse of Drugs. Available at: www.talktofrank.com/drug/cannabis. [June 2013].
107. K. Smith, J. Flatley. Drug Misuse Declared: Findings from the 2010/11 British Crime Survey England and Wales, 2011, Home Office Statistical Bulletin (HOSB). ISBN 1759 7005. London, UK.
108. W.A. Devane, A. Breuer, T. Sheskin, T.U. Järbe, M.S. Eisen, R. Mechoulam. A novel probe for the cannabinoid receptor. J. Med. Chem. 1992, 35, 2065.
109. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA Insights Series No 8, Drug use impaired driving and traffic accidents. Office for Official Publications of the European Communities, Lisbon, 2008.
110. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Action on new drugs briefing paper: Understanding the 'Spice' phenomenon. EMCDDA, Lisbon, 2009.
111. A.A. Westin, W.R. Brede, K.A. Espnes. Synthetic cannabis, English abstract. Tidsskr. Nor. Laegeforen. 2012, 132, 2289.
112. J.Y. Yeakel, B.K. Logan. Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J. Anal. Toxicol. 2013, 37, 547.
113. R. Kronstrand, M. Roman, M. Andersson, A. Eklund. Toxicological findings of synthetic cannabinoids in recreational users. J. Anal. Toxicol. 2013, 37, 534.
114. W.C. Rodrigues, P. Catbagan, S. Rana, G. Wang, C. Moore. Detection of synthetic cannabinoids in oral fluid using ELISA and LC-MS-MS. J. Anal. Toxicol. 2013, 37, 526.
115. D. Giovanardi, C.N. Castellana, S. Pisa, B. Poppi, D. Pinetti, A. Bertolini, A. Ferrari. Prevalence of abuse of alcohol and other drugs among injured drivers presenting to the emergency department of the University Hospital of Modena, Italy. Drug Alcohol Depend. 2005, 80, 135.
116. E. Romano, R.B. Voas, Drug and alcohol involvement in four types of fatal crashes. J. Stud. Alcohol Drugs 2011, 72, 567.
117. K. Terhune, C. Ippolito, D. Hendricks, Y.G. Michalovic, S.C. Bogema, P. Santinga, R. Blomber, D.F. Preusser. The incidence and role of drugs in fatally injured drivers. National Highway Traffic Safety Administration, Department of Transportation, Washington, DC, USA, 1992.
118. A.F. Williams, M.A. Peat, D.J. Crouch, J.K. Wells, B.S. Finkle. Drugs in fatally injured young male drivers. Public Health Rep. 1985, 100, 19.
119. C.E. Hunter, R.J. Lokan, M. Longo, J. White, M. White. The prevalence and role of alcohol, cannabinoids, benzodiazepines and stimulants in non-fatal crashes. Forensic Science, Department for Administrative and Information Services, Adelaide, Australia, 1998.
120. A. Crancer Jr, A. Crancer. The Involvement of Cannabis in California Fatal Motor Vehicle Crashes, 1998-2008. Available at: http://druggeddriving.org/pdfs/CAMJStudyJune2010.pdf [May 2013]
121. D.M. Fergusson, L. Horwood, J.M. Boden. Is driving under the influence of cannabis becoming a greater risk to driver safety than drink driving? Findings from a longitudinal study. Accident Anal. Prev. 2008, 40, 1345.
122. O.H. Drummer. A review of the contribution of drugs in drivers to road accidents. in Inquiry into the effects of drugs (other than alcohol) on road safety in Victoria, incorporating collected papers. LV North, Government Printer, Australia, 1995, pp. 1-28.
123. M.C. Longo, C.E. Hunter, R.J. Lokan, J.M. White, M.A. White. The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability. Accident Anal. Prev. 2000, 32, 623.
124. M.C. Longo, C.E. Hunter, R.J. Lokan, J.M. White, M.A. White. The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: Part ii: The relationship between drug prevalence and drug concentration, and driver culpability. Accident Anal. Prev. 2000, 32, 623.
125. G.B. Chesher. The effects of alcohol and marijuana in combination: a review. Alcohol 1986, 2, 105.
126. Driving under the Influence of Drugs, Alcohol and Medicines (DRUID). Prevalence of alcohol and other psychoactive substances in injured and killed drivers. Available at: http://www.west-info.eu/files/Druid-report-08-2011.pdf [June 2013].
127. B. Gadegbeku, E. Amoros, and the SAM group. 6th Framework programme. Deliverable 2.3.2., Relative risk estimates for alcohol and other psychoactive substances impaired drivers in fatal accidents, based on the DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups 130 responsibility approach in France. Driving under the Influence of Drugs, Alcohol and Medicines (DRUID), 2010. [June 2013].
128. K.M. Dubowski, N.A. Essary. Measurement of low breath-alcohol concentrations: Laboratory studies and field experience. J. Anal. Toxicol. 1999, 23, 386.
129. K. Wolff. Biological markers of drug use. in Addiction Psychiatry, Psychiatry, (Eds: E.J. Marshall, M. Farrell). The Medicine Pub Co Ltd, London, 2007.
130. P. Lafolie, O. Beck, G. Blennow, L. Boréus, S. Borg, C.E. Elwin, L. Karlsson, G. Odelius, P. Hjemdahl. Importance of creatinine analyses of urine when screening for abused drugs. Clin. Chem. 1991, 37, 1927.
131. M.-B. Biecheler. Cannabis, driving and road safety: A review of the scientific literature, Driving under the Influence of Drugs, Alcohol and Medicines (DRUID) Deliverable 2.1.3. www.druid-project.eu. [June 2013].
132. M.N. Bates, T.A. Blakely. Role of cannabis in motor vehicle crashes. Epidemiol. Rev. 1999, 21, 222.
133. Ogden E.J., Moskowitz H. Effects of alcohol and other drugs on driver performance. Traffic Inj. Prev. 2004 5, 185.
134. A. Verstraete, A. Knoche, R. Jantos, G. Skopp, H. Gjerde, V. Vindenes, J. Mørland, K. Langel, P. Lillsunde. Per se limits - Methods of defining cut-off values for zero tolerance. Driving under the Influence of Drugs, Alcohol and Medicines (DRUID). 6th Framework Program, Deliverable 1.4.2. BASt. 2011.
135. O.H. Drummer. Drug testing in oral fluid. Clin. Biochem. Rev. 2006, 27, 147.
136. D. Lee, R. Vandrey, D.R. Mendu, S. Anizan, G. Milman, J.A. Murray, A.J. Barnes, M.A. Huestis. Oral fluid cannabinoids in chronic cannabis smokers during rral Δ9-Tetrahydro cannabinol therapy and smoked cannabis challenge. Clin. Chem. 2013, Epub ahead of print.
137. J.A. Henry, K. Ohashi, J. Wadsworth, P. Turner. Drug recovery following buccal absorption of propranolol. Brit. J. Clin. Pharmacol. 1980, 10, 61.
138. Niedbala R.S., Kardos K.W., Fritch D.F., Kunsman K.P., Blum K.A., Newland G.A., Waga J., Kurtz L., Bronsgeest M., Cone E.J. Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle. J. Anal. Toxicol. 2005, 29, 607.
139. G.F. Kauert, J.G. Ramaekers, E. Schneider, M.R. Moeller, S.W. Toennes. Pharmacokinetic properties of delta9-tetrahydro cannabinol in serum and oral fluid. J. Anal. Toxicol. 2007, 31, 288.
140. M.A. Huestis, E.J. Cone. Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J. Anal. Toxicol. 2004, 28, 394.
141. M. Laloup, M. Del Mar Ramirez Fernandez, M. Wood, G. De Boeck, V. Maes, N. Samyn. Correlation of Delta9-tetrahydro cannabinol concentrations determined by LC-MS-MS in oral fluid and plasma from impaired drivers and evaluation of the on-site Dräger Drug Test. Forensic Sci. Int. 2006, 161, 175.
142. J. Davey, J. Freeman. Screening for drugs in oral fluid: drug driving and illicit drug use in a sample of Queensland motorists. Traff Inj. Prev. 2009, 10, 231.